The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

26 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.EBI
Universit£
Evaluation of bisbenzamidines as inhibitors for matriptase-2.EBI
University Of Bonn
Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.EBI
Southern Research
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.EBI
Aurigene Discovery Technologies
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.EBI
Washington University
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.EBI
Washington University
Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2.EBI
Universit£
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.EBI
Aurigene Discovery Technologies
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.EBI
Universit£
Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.EBI
Aurigene Discovery Technologies
1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.EBI
Universit£
Design and synthesis of potent, selective inhibitors of matriptase.EBI
TBA
Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.EBI
University Of Maryland
Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.EBI
Philipps University Marburg
Identification of the first low-molecular-weight inhibitors of matriptase-2.EBI
University Of Bonn
Substrate specificity and inhibitory study of human airway trypsin-like protease.EBI
Faculty Of Chemistry Gdansk University
Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.EBI
The Medicines Company (Leipzig)
Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors.EBI
Curacyte Discovery
Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase.EBI
National Cancer Institute-Frederick
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.EBI
Georgetown University Medical Center
Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.EBI
Aarhus University
Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1.EBI
The University Of Queensland
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.EBI
Bicycle Therapeutics
Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5'-nucleotidase.BDB
Quaid-I-Azam University